Human papillomavirus vaccine: progress and the future

Bibliography

• ANDERSON GH, BOYES DA, BENEDET JL et al.: Organization and results of the cervical cytology screening programme in British Columbia, 1955-85. Br. Med. J. (Clin. Res. Ed.) (1988) 296(6627):975-978.
   PubMed Web of Science ®Google Scholar
• SUNG HY, KEARNEY KA, MILLER M et al.: Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer (2000) 88(10):2283-2289.
   PubMed Web of Science ®Google Scholar
• AMERICAN CANCER SOCIETY: Cancer Facts and Figures 2006. American Cancer Society, Atlanta, GA, USA (2006).
   Google Scholar
• LEE C-L, KO Y-C: Hepatitis B vaccination and hepatocellular carcinoma in Taiwan. Pediatrics (1997) 99(3):351-353.
   PubMed Web of Science ®Google Scholar
• MUÑOZ N, BOSCH FX, DE SANJOSÉ S et al.: The causal link between human papillomavirus and invasive cervical cancer: a population-based, case-control study in Colombia and Spain. Int. J. Cancer (1992) 52:743-749.
   PubMed Web of Science ®Google Scholar
• WALBOOMERS JM, JACOBS MV, MANOS MM et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. (1999) 189(1):12-19.
   PubMed Web of Science ®Google Scholar
• CLIFFORD GM, SMITH JS, PLUMMER MS et al.: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer (2003) 88(1):63-73.
   PubMed Web of Science ®Google Scholar
• BOSCH FX, LORINCZ A, MUNOZ N, MEIJER CJ, SHAH KV et al.: The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. (2002) 55(4):244-265.
   Google Scholar
• BOSCH FX, MANO MM, MUNOZ N et al.: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl Cancer Inst. (1995) 87(11):796-802.
   PubMed Web of Science ®Google Scholar
• VAN BALLEGOOIJEN M, VAN DAN AKKER-VAN MARLE ME, WARMERDAM PG, MEIJER CJ, WALBOOMERS JM, HABBEMA JD: Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost) effectiveness. Br. J. Cancer (1997) 76(5):651-657.
   PubMed Web of Science ®Google Scholar
• PRETORIUS RG, PETERSON P, AZIZI F, BURCHETTE RJ: Subsequent risk and presentation of cervical intraepithelial neoplasia (CIN) 3 or cancer after a colposcopic diagnosis of CIN 1 or less. Am. J. Obstet. Gynecol. (2006) 195(5):1260-1265.
   Google Scholar
• OSTOR AG: Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol. (1993) 12(2):186-192.
   PubMed Web of Science ®Google Scholar
• HOWLEY PM: Papillomavirinae: the viruses and their replication. In: Fields Virology. 3rd ed. Fields BN, Knipe DM, Howley PM (Eds), Lippincott-Raven, Philadelphia, PA, USA (1996):2045-2076.
   Google Scholar
• KIRNBAUER R: Papillomavirus-like particles for serology and vaccine development. Intervirology (1996) 39(1-2):54-61.
   PubMed Web of Science ®Google Scholar
• JABBAR IA, FERNANDO GJ, SAUNDERS N et al.: Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine (2000) 18(22):2444-2453.
   PubMed Web of Science ®Google Scholar
• KIM JW, HUNG CF, JUANG J et al.: Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther. (2004) 11(12):1011-1018.
   PubMed Web of Science ®Google Scholar
• HENDERSON RA, MOSSMAN S, NAIRN N, CHEEVER MA: Cancer vaccines and immunotherapies: emerging perspectives. Vaccine (2005) 23(17-18):2359-2362.
   PubMed Web of Science ®Google Scholar
• SANTIN AD, HERMONAT PL, RAVAGGI A et al.: Induction of human papillomavirus-specific CD4(+) and CD8 (+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus Type 16- and 18-positive cervical cancer. J. Virol. (1999) 73(7):5402-5410.
   PubMed Web of Science ®Google Scholar
• KIM TW, HUNG CF, ZHENG M et al.: A DNA vaccine co-expressing antigen and an anti-apoptotic molecule further enhances the antigen-specific CD8+T-cell immune response. J Biomed Sci. (2004) 11(4):493-499.
   PubMed Web of Science ®Google Scholar
• KIM TW, HUNG CF, JUANG J, HE L, HARDWICK JM, WU TC: Enhancement of suicidal DNA vaccine potency by delaying sucidal DNA-induced cell death. Gene Ther. (2004) 11(3):336-342.
   PubMed Web of Science ®Google Scholar
• DANIEL D, CHIU C, GIRAUDO E et al.: CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res. (2005) 65(5):2018-2025.
   PubMed Web of Science ®Google Scholar
• VANDEPAPELIERE P, BARRASSO R, MEIJER CJ et al.: Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J. Infect. Dis. (2005) 192(12):2099-107.
   PubMed Web of Science ®Google Scholar
• HARRO CD, PANG YY, RODEN RB et al.: Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl Cancer Inst. (2001) 93(4):284-292.
   Google Scholar
• HARPER DM, FRANCO EL, WHEELER CM et al.: Sustained efficacy up to 4.5 years of bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: followup from a randomized control trial. Lancet (2006) 367(9518):1247-1255.
   PubMed Web of Science ®Google Scholar
• MUNOZ N, BOSCH FX, CASTELLSAGUE X et al.: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer (2004) 111(2):278-285.
   Web of Science ®Google Scholar
• KOUTSKY LA, AULT KA, WHEELER CM et al.: A controlled trial of a human papillomavirus Type 16 vaccine. N. Engl. J. Med. (2002) 347(21):1645-1651.
   PubMed Web of Science ®Google Scholar
• VILLA LL, COSTA RL, PETTA CA et al.: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in young women, a randomized double-blind controlled multicentre Phase II efficacy trial. Lancet Oncol. (2005) 6(5):271-278.
   PubMed Web of Science ®Google Scholar
• HARPER DM, FRANCO EL, WHEELER C et al.: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet (2004) 364(9447):1757-1765.
   PubMed Web of Science ®Google Scholar
• GRUNBAUM JA, KANN L, KINCHEN S et al.: Youth risk behavior suveillance-United States, 2003. MMWR Surveill. Summ. (2004) 53(SS-2):1-95.
   PubMedGoogle Scholar
• WINER RL, LEE S, HUGHES JP, ADAM DE, KIVIAT NB, KOUTSKY LA: Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am. J. Epidemiol. (2002) 157(3):218-226.
   Web of Science ®Google Scholar
• VAN GRIENSVAN F, KEAWKUNGWAL J, TAPPERO JW et al.: Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand. AIDS (2004) 18(2):295-301.
   PubMed Web of Science ®Google Scholar
• KAHN JA, ROSENTHAL SL, HAMANN T, BERNSTEIN DL: Attitudes about human papillomavirus vaccine in young women. Int. J. STD AIDS (2003) 14(5):300-306.
   Web of Science ®Google Scholar
• WASHAM C: Targeting teens and adolescents for HPV vaccine could draw fire. J. Natl Cancer Inst. (2005) 97(14):1030-1031.
   PubMed Web of Science ®Google Scholar
• POLAND GA, JACOBSON RM, KOUTSKY LA et al.: Immunogenicity and reacto-genicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial. Mayo Clin. Proc. (2005) 80(5):601-610.
   Google Scholar
• GOLDIE SJ, KOHLI M, GRIMA D et al.: Projected clinical benefits and cost effectiveness of a human papillomavirus 16/18 vaccine. J. Natl Cancer Inst. (2004) 96(8):604-615.
   PubMed Web of Science ®Google Scholar
• KULASINGAM SL, MYERS ER: Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA (2003) 290(6):781-789.
   PubMed Web of Science ®Google Scholar
• ZIMET GD, MAYS RM, WINSTON Y, KEE R, DICKES J, SU L: Acceptability of human papillomavirus immunization. J. Womens Health Gend. Based Med. (2000) 9(1):47-50.
   PubMedGoogle Scholar
• RALEY JC, FOLLOWWILL KA, ZIMET GD, AULT KA: Gynecologists’ attitudes regarding HPV vaccination: a survey of Fellows of the American College of Obstetrics and Gynecologists. Infect. Dis. Obstet. Gynecol. (2004) 12(3-4):127-133.
   PubMedGoogle Scholar
• LAZCANO-PONCE E, RIVERA L, ARILLO-SANTILLAN E, SALMERON J, HERNANDEZ-AVILA M, MUNOZ N: Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico. Arch. Med. Res. (2001) 32(3):243-247.
   PubMed Web of Science ®Google Scholar
• FREED GL, BORDLEY WC, CLARK SJ, KONRAD TR: Universal hepatitis B immunizations of infants: reactions of pediatricians and family physicians over time. Pediatrics (1994) 93(5):747-751.
   PubMed Web of Science ®Google Scholar
• PARTRIDGE JM, KOUTSKY LA: Genital human papillomavirus infection in men. Lancet Infect. Dis. (2006) 6(1):21-31.
   PubMed Web of Science ®Google Scholar
• HILLEMAN MR: Past, present, and future of measles, mumps, and rubella virus vaccines. Pediatrics (1992) 90(1):149-153.
   PubMed Web of Science ®Google Scholar